Company: TEVA Pharmaceuticals Ireland. Legal category: Prescription. GMS. Sport Permitted. Active ingredient: Risperidone 1mg, 2mg, 3mg, 4mg. Description: White, pale brown, yellow or pale green respectively, round, bevelled biconvex film-coated tablets, scored and marked with RIS above the score line and strength under the score line on one side. Presentation: 1mg-20, €13.48; 60, €40.40; 2mg-60, [...]
Company: Pfizer Healthcare Ireland. Legal category: Hospital. Sport Permitted. Active ingredient: Anidulafungin 100mg. The reconstituted solution contains 3.33mg/ml anidulafungin and the diluted solution contains 0.36mg/ml anidulafungin. Description: 100mg powder and 30ml solvent for concentrate for solution for infusion in vials. Presentation: 1 vial powder + 1 vial solvent, €483.42. Indications: Treatment of invasive candidiasis in [...]
Company: Pfizer Healthcare Ireland. Legal category: Hospital. Sport Permitted. Active ingredient: Maraviroc 150mg, 300mg. Description: Blue, biconvex, oval film-coated tablets marked Pfizer on one side and MVC150 or MVC300 on reverse. Presentation: 60, €966. Indications: As part of an antiretroviral combination regimen in treatment-experienced adult patients infected with only CCR5-tropic HIV-1 detectable. Pharmacology: Maraviroc is [...]
Company: Astellas Pharma Co. Ltd. Legal category: Prescription. HT. Sport Permitted. Active ingredient: Tacrolimus 0.5mg, 1mg, 5mg. Description: Yellow-orange, white-orange, greyish red-orange gelatin capsules imprinted in red with 0.5mg, 1mg, 5mg on the capsule cap and *647, *677, *687 respectively on the orange capsule body. Presentation: 50, price available on request. Indications: Prophylaxis of transplant [...]
Wyeth is pleased to announce the launch of Efexor XL 37.5mg for use in Panic Disorder, with or without agoraphobia. Panic disorder is characterised by recurrent, unexpected panic attacks; i.e., a discrete period of intense fear or discomfort in the absence of real danger, with 13 specific symptoms including accelerated heart rate, shortness of breath, [...]
Pivotal Mircera study first to convert dialysis patients from frequent dosing directly to once every four weeks. A pivotal study published in the Lancet has shown that dialysis patients can be effectively switched from frequently dosed anaemia drugs to an innovative new anaemia treatment, Mircera, that can be administered once a month.1 Renal anaemia is [...]
Loading ...
